IV PPI Duration for Upper GI Bleeding

Initial Management

The American College of Emergency Physicians recommends starting PPI therapy immediately upon presentation, even before endoscopy, with either pantoprazole or omeprazole 80 mg IV bolus, to reduce stigmata of recent bleeding at index endoscopy and decrease the need for endoscopic therapy, though it does not replace the need for urgent endoscopy 4, 2
Pre-endoscopy PPI administration may reduce the need for endoscopic therapy in patients with upper GI bleeding, with a study demonstrating a decrease in the need for endoscopic therapy, though the strength of evidence is moderate 5, 4

The European Society of Gastrointestinal Endoscopy recommends continuing the high-dose regimen (8 mg/hour continuous infusion) for exactly 72 hours after endoscopic hemostasis, specifically for patients with high-risk stigmata who have undergone successful endoscopic therapy, with a randomized trial of 767 patients demonstrating significant reduction in rebleeding (5.9% vs 10.3%, p=0.03) with this regimen, and the strength of evidence is high 5, 4, 1
The 72-hour duration is based on evidence showing that rebleeding risk is highest during the first three days, with the American College of Gastroenterology recommending this protocol for patients with high-risk stigmata 1, 2

The American College of Gastroenterology recommends transitioning to oral PPI twice daily through day 14 after completing the 72-hour IV infusion, and then switching to once-daily oral PPI therapy from day 14 onward, with the goal of allowing complete mucosal healing 1, 2
The European Society of Gastrointestinal Endoscopy recommends continuing total PPI therapy for 6-8 weeks following endoscopic treatment to allow complete mucosal healing, with a study demonstrating that discontinuing PPI therapy before 6-8 weeks may not allow adequate time for mucosal healing, and the strength of evidence is moderate 5, 4, 3

The American College of Gastroenterology and European Society of Gastrointestinal Endoscopy recommend that PPI therapy is not a substitute for endoscopic hemostasis, and urgent endoscopy should not be delayed while relying solely on pharmacologic therapy, with the strength of evidence being high 5, 4, 3
The benefits of high-dose PPI therapy are most pronounced in patients with high-risk endoscopic stigmata, with a study demonstrating significant reduction in rebleeding in this population, and the strength of evidence is high 1, 2
Discontinuing PPI therapy before 6-8 weeks may not allow adequate time for mucosal healing, with the American College of Gastroenterology recommending against this practice, and the strength of evidence is moderate 2, 3

The American College of Gastroenterology recommends testing all patients for Helicobacter pylori and providing eradication therapy if positive, with the goal of reducing the risk of rebleeding, and the strength of evidence is high 1, 2
The European Society of Gastrointestinal Endoscopy recommends restarting aspirin within 3-5 days and continuing with PPI co-therapy for patients requiring cardiovascular prophylaxis with antiplatelet therapy, with the goal of reducing the risk of cardiovascular complications, and the strength of evidence is moderate 2